Privia Health (PRVA) furnishes third quarter 2025 results release

Privia Health Group, Inc. furnished an 8-K announcing its financial results for the third quarter ended September 30, 2025.

Accepted by SEC EDGAR 11/06/2025 - 06:09 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Privia Health Group, Inc. furnished an 8-K announcing its financial results for the third quarter ended September 30, 2025. The company issued a press release on November 6, 2025, attached as Exhibit 99.1.

The information under Item 2.02, including Exhibit 99.1, is stated as “furnished” and not “filed” under the Exchange Act. Privia Health’s common stock trades on the Nasdaq Global Select Market under the symbol PRVA.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Privia Health (PRVA) disclose in this 8-K?

The company furnished a press release announcing its financial results for the third quarter ended September 30, 2025.

When was the press release issued by Privia Health (PRVA)?

The press release was issued on November 6, 2025 and is attached as Exhibit 99.1.

Is the information in this 8-K considered filed or furnished?

The Item 2.02 information, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act.

Which period do the announced results cover for PRVA?

The press release covers results for the third quarter ended September 30, 2025.

What exhibits are included with Privia Health’s 8-K?

The filing includes Exhibit 99.1: Privia Health Group, Inc. press release dated November 6, 2025.

On which exchange does PRVA trade and under what symbol?

Privia Health’s common stock trades on the Nasdaq Global Select Market under the symbol PRVA.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001759655FALSE00017596552025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________________

FORM 8-K

_______________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2025

_________________________

Privia Health Group, Inc.

(Exact Name of Registrant as Specified in Its Charter)

_________________________

Delaware						001-40365			81-3599420
(State or other jurisdiction of incorporation or organization)						(Commission File No.)			(I.R.S. Employer Identification No.)
950 N. Glebe Rd.,
Suite 700
Arlington,			Virginia						22203
(Address of Principal Executive Offices)									(Zip Code)

(571) 366-8850

Registrant's telephone number, including area code

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Check the appropriate box below if the form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2 (b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, $0.01 par value per share			PRVA			The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2025, Privia Health Group, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, are “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibit:

Exhibit No.						Description
99.1						Privia Health Group, Inc. Press Release Dated November 6, 2025
104						The Cover Page from this Current Report on Form 8-K, Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						PRIVIA HEALTH GROUP, INC.
Date: November 06, 2025						By:			/s/ David Mountcastle
									Name: David Mountcastle
									Title: Executive Vice President, Chief Financial Officer and Authorized Officer